Seminal plasma proteins in prostatic carcinoma: increased nuclear semenogelin I expression is a predictor of biochemical recurrence after radical prostatectomy
Seminal plasma proteins in prostatic carcinoma: increased nuclear semenogelin I expression is a predictor of biochemical recurrence after radical prostatectomy
复制标题
DOI：
10.1016/j.humpath.2012.02.008
复制
发表时间：
2012-11-01
期刊：
影响因子：
3.3
通讯作者：
Miyamoto, Hiroshi
中科院分区：
文献类型：
--
作者：
Izumi, Koji;Li, Yi;Miyamoto, Hiroshi
Semenogelins 和 eppin 是精浆蛋白，可形成复合物并抑制精子活力。然而，人们对这些蛋白质在前列腺癌中的作用知之甚少。我们对 291 例根治性前列腺切除术标本中的精蛋白 I 和 II 以及 eppin 进行了免疫组织化学染色。然后，我们评估了它们在良性/高级前列腺上皮内瘤变/癌细胞的细胞核、细胞质或管腔内分泌物中的表达与我们的患者队列可用的临床病理学特征之间的关联。染色呈阳性的比例为 32%/77%/84%（核精蛋白 I）、87%/94%/84%（核精蛋白 II）、56%/64%/37%（核 eppin）、7%/15%/11%（细胞质精蛋白 I）、6%/11%/9%（细胞质精蛋白 I）良性/前列腺上皮内瘤变/癌分别为 68%/74%/95%（细胞质 eppin）、97%/98%/13%（分泌型精蛋白 I）、98%/97%/11%（分泌型精蛋白 11）和 97%/98%/48%（分泌型 eppin）。癌中核精蛋白 I/细胞质 eppin 的水平显着高于良性 (P < .001/P < .001) 或前列腺上皮内瘤变 (P < .001/P < .001)，且前列腺上皮内瘤变中显着高于良性 (P < .001/P = .006)。前列腺上皮内瘤变中的核精蛋白 11 表达显着高于良性 (P < .001) 或癌 (P < .001)。与良性 (P < .001) 或前列腺上皮内瘤变 (P < .001) 相比，癌症中的核 eppin 表达显着降低。癌中分泌的精蛋白 I、分泌的精蛋白 II 和分泌的 eppin 均显着低于良性 (P < .001) 或前列腺上皮内瘤变 (P < .001)。除了格里森评分 8 或更高的肿瘤中核 eppin 表达显着降低之外，每种染色与临床病理特征之间没有统计学上显着的相关性。 Kaplan-Meier 和时序检验进一步显示，核精蛋白 I 阳性肿瘤患者的生化复发风险显着较高 (P = .046)。多变量 Cox 模型显示核精蛋白 I 阳性作为复发的独立预测因子具有显着性趋势 (P = .093)。这些结果表明，核精蛋白表达可能是接受根治性前列腺切除术的男性的可靠预测指标。 (C) 2012 Elsevier Inc. 保留所有权利。
Semenogelins and eppin are seminal plasma proteins that form a complex and inhibit sperm motility. However, the role of these proteins in prostate cancer is poorly understood. We immunohistochemically stained for semenogelins I and II and eppin in 291 radical prostatectomy specimens. We then evaluated the association between their expressions in nuclei, cytoplasms, or intraluminal secretions of benign/high-grade prostatic intraepithelial neoplasia/carcinoma cells and clinicopathologic profile available for our patient cohort. Stains were positive in 32%/77%/84% (nuclear semenogelin I), 87%/94%/84% (nuclear semenogelin II), 56%/64%/37% (nuclear eppin), 7%/15%/11% (cytoplasmic semenogelin I), 6%/11%/9% (cytoplasmic semenogelin 11), 68%/74%/95% (cytoplasmic eppin), 97%/98%/13% (secreted semenogelin I), 98%/97%/11% (secreted semenogelin 11), and 97%/98%/48% (secreted eppin) of benign/prostatic intraepithelial neoplasia/carcinoma, respectively. The levels of nuclear semenogelin I/cytoplasmic eppin were significantly higher in carcinoma than in benign (P < .001/P < .001) or prostatic intraepithelial neoplasia (P < .001/P < .001) and in prostatic intraepithelial neoplasia than in benign (P < .001/P = .006). Significantly higher nuclear semenogelin 11 expression was found in prostatic intraepithelial neoplasia than in benign (P < .001) or carcinoma (P < .001). Significantly lower nuclear eppin expression was seen in carcinoma than in benign (P < .001) or prostatic intraepithelial neoplasia (P < .001). Secreted semenogelin I, secreted semenogelin II, and secreted eppin were all significantly lower in carcinoma than in benign (P < .001) or prostatic intraepithelial neoplasia (P < .001). There were no statistically significant correlations between each stain and clinicopathologic features except significantly lower nuclear eppin expression in Gleason score 8 or higher tumors. Kaplan-Meier and log-rank tests further revealed that patients with nuclear semenogelin I positive tumor had a significantly higher risk for biochemical recurrence (P = .046). Multivariate Cox model showed a trend toward significance (P = .093) in nuclear semenogelin I positivity as an independent predictor for recurrence. These results suggest that nuclear semenogelin expression could be a reliable prognosticator in men who undergo radical prostatectomy. (C) 2012 Elsevier Inc. All rights reserved.